Pyrazoloquinazoline Tricyclic System as Novel Scaffold to Design New Kinase CK2 Inhibitors

Authors: Moro, Stefano; Varano, Flavia; Cozza, Giorgio; Pagano, Mario A.; Zagotto, Giuseppe; Chilin, Adriana; Guiotto, Adriano; Catarzi, Daniela; Calotta, Vittoria; Pinna, Lorenzo A.

Source: Letters in Drug Design & Discovery, Volume 3, Number 4, May 2006 , pp. 281-284(4)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Casein kinase 2 (CK2) is a ubiquitous, essential, and highly pleiotropic protein kinase whose abnormally high constitutive activity is suspected to underlie its pathogenic potential in neoplasia and infective diseases. Using a combined virtual screening approach, we have identified the pyrazoloquinazoline tricyclic system as a novel scaffold to design new kinase CK2 inhibitors.

Keywords: Kinase CK2; CK2 inhibitors; virtual screening

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157018006776743233

Affiliations: 1: Molecular Modeling Section, Department of Pharmaceutical Sciences, University of Padova, Via Marzolo, 5, 35131 Padova, Italy.

Publication date: 2006-05-01

More about this publication?

Letters in Drug Design & Discovery publishes original letters on all areas of rational drug design and discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of Internet technology for both the submission and review of manuscripts. The journal is essential reading to all pharmaceutical scientists involved in research in drug design and discovery.